Clinical and Translational Oncology

, Volume 18, Issue 9, pp 901–908 | Cite as

Quality of life in patients treated by adjuvant radiotherapy for endometrial and cervical cancers: correlation with dose–volume parameters

  • C. Pisani
  • L. Deantonio
  • D. Surico
  • M. Brambilla
  • A. Galla
  • E. Ferrara
  • L. Masini
  • G. Gambaro
  • N. Surico
  • M. KrengliEmail author
Research Article



Modern multidisciplinary cancer treatments aim at obtaining minimal influence on patients’ quality of life (QoL). The purpose of this study was to assess QoL and correlate it with dose–volume parameters of organ at risks (OARs) in patients who received adjuvant radiotherapy for endometrial and cervical cancers.

Materials and methods

We administered the EORTC QLQ-C30 and EN24 or CX24 questionnaires to 124 patients, 100 with endometrial cancer and 24 with cervical cancer treated with postoperative radiotherapy ± chemotherapy in regular follow-up. Bladder function, fecal incontinence or urgency and sexual functioning were investigated and correlated with dose–volume parameters of OAR by multiple linear regression analysis. This correlation was assessed by R 2 value.


QoL was very high in the majority of patients (82.3 % of patients). Few patients referred urinary incontinence (3.2 %) or abdominal discomfort of high grade (4.0 %). We found a significant correlation between bladder V40, i.e., absolute percentage of bladder volume that received a dose of 40 Gy, and global health status (p < 0.05, R 2 = 0.17), urinary urgency (p < 0.05, R 2 = 0.24), urinary incontinence (p < 0.05, R 2 = 0.23) and dyspareunia (p < 0.05, R 2 = 0.04). We found also a correlation between global health status and mean dose to vagina (p < 0.05, R 2 = 0.17) and between maximum dose to lumbo-sacral plexus and abdominal pain (p < 0.05, R 2 = 0.07).


Women treated with surgery and adjuvant radiotherapy for endometrial and cervical cancers have good QoL with minimal limitations of daily activities. QoL was correlated with dose–volume parameters such as bladder V40, mean dose to vagina, maximum dose to trigone and LSP.


Quality of life Endometrial cancer Cervical cancers Adjuvant radiotherapy Dose–volume parameters 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.


  1. 1.
    Vaz AF, Conde DM, Costa-Paiva L, Morais SS, Esteves SB, Pinto-Neto AM. Quality of life and adverse events after radiotherapy in gynecologic cancer survivors: a cohort study. Arch Gynecol Obstet. 2011;284:1523–31.CrossRefGoogle Scholar
  2. 2.
    Peters WA III, Liu PY, Barett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.PubMedGoogle Scholar
  3. 3.
    Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery vs radiotherapy for stage Ib–IIa cervical cancer. Lancet. 1997;350:535–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Querleu D, Morrow CP. Classification of radical hysterectomy. Gynecol Oncol. 2009;115:314–5.CrossRefPubMedGoogle Scholar
  5. 5.
    NCCN clinical practice guidelines in Oncology: cervical cancer version 2.2015. NCCN clinical practice guidelines in Oncology: endometrial uterine neoplasms version 2.2015.
  6. 6.
    Small W Jr, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:428–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. GEC ESTRO Working Group. Radiother Oncol. 2006;78:67–77.CrossRefPubMedGoogle Scholar
  8. 8.
    Gay HA, Barthold HJ, O’Meara E, Bosch WR, El Naqa I, Al-Lozi R, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83:353–62.CrossRefGoogle Scholar
  9. 9.
    Yi SK, Mak W, Yang CC, Liu T, Cui J, Chen AM, et al. Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of radiation-induced lumbosacral plexopathy. Int J Radiat Oncol Biol Phys. 2012;84:376–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Mirabeau-Beale KL, Viswanathan AN. Quality of life (QoL) in women treated for gynecologic malignancies with radiation therapy: a literature review of patient-reported outcomes. Gynecol Oncol. 2014;134:403–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009;27:3547–56.CrossRefPubMedGoogle Scholar
  13. 13.
    Vaz AF, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Esteves SB. Quality of life and acute toxicity of radiotherapy in women with gynecologic cancer: a prospective longitudinal study. Arch Gynecol Obstet. 2008;278:215–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Fang P, Tan KS, Grover S, McFadien MK, Troxel AB, Lin L. Psychosocial encounters correlates with higher patient-reported functional quality of life in gynaecological cancer patients receiving radiotherapy. Radiat Oncol. 2015;10:34–41.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2003;56:937–49.CrossRefPubMedGoogle Scholar
  16. 16.
    Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Early-stage cervical carcinoma, radical hysterectomy, and sexual function. A longitudinal study. Cancer. 2004;100:97–106.CrossRefPubMedGoogle Scholar
  17. 17.
    Bukovic D, Strinic T, Habek M, Hojsak I, Silovski H, Krhen I, et al. Sexual life after cervical carcinoma. Coll Antropol. 2003;27:173–80.PubMedGoogle Scholar
  18. 18.
    Katepratoom C, Manchana T, Amornwichet N. Lower urinary tract dysfunction and quality of life in cervical cancer survivors after concurrent chemoradiation versus radical hysterectomy. Int Urogynecol J. 2014;25:91–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Lind H, Waldenström AC, Dunberger G, Al-Abany M, Alevronta E, Johansson KA, et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. Br J Cancer. 2011;105:737–45.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dahele M, Davey P, Reingold S, Shun Wong C. Radiation-induced lumbo-sacral plexopathy (RILSP): an important enigma. Clin Oncol. 2006;18:427–8.CrossRefGoogle Scholar
  21. 21.
    Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005;23:7428–36.CrossRefPubMedGoogle Scholar
  22. 22.
    Gondi V, Bentzen SM, Sklenar KL, Dunn EF, Petereit DG, Tannehill SP, et al. Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. Int J Radiat Oncol Biol Phys. 2012;84:973–82.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rodrigues AC, Teixiera R, Teixeira T, Conde S, Soares P, Torgal I. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet. 2012;285:505–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Stinesen Kollberg K, Waldenström AC, Bergmark K, Dunberger G, Rossander A, Wilderäng U, et al. Reduced vaginal elasticity, reduced lubrication, and deep and superficial dyspareunia in irradiated gynecological cancer survivors. Acta Oncol. 2015;54:772–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Froeding LP, Ottosen C, Rung-Hansen H, Svane D, Mosgaard BJ, Jensen PT. Sexual functioning and vaginal changes after radical vaginal trachelectomy in early stage cervical cancer patients: a longitudinal study. J Sex Med. 2014;11:595–604.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  • C. Pisani
    • 1
    • 2
  • L. Deantonio
    • 1
    • 2
  • D. Surico
    • 2
    • 3
  • M. Brambilla
    • 4
  • A. Galla
    • 1
    • 2
  • E. Ferrara
    • 1
    • 2
  • L. Masini
    • 1
  • G. Gambaro
    • 1
  • N. Surico
    • 2
    • 3
  • M. Krengli
    • 1
    • 2
    Email author
  1. 1.Department of RadiotherapyUniversity Hospital Maggiore della CaritàNovaraItaly
  2. 2.Chair of Radiotherapy, Department of Translational MedicineUniversity of “Piemonte Orientale”NovaraItaly
  3. 3.Department of Obstetrics and GynecologyUniversity Hospital Maggiore della CaritàNovaraItaly
  4. 4.Department of Medical PhysicsUniversity Hospital Maggiore della CaritàNovaraItaly

Personalised recommendations